TY - JOUR
T1 - Developments for a growing Japanese patient population: Facilitating new technologies for future health care
AU - Kato, Harubumi
AU - Nishimura, Toshihide
AU - Ikeda, Norihiko
AU - Yamada, Tesshi
AU - Kondo, Tadashi
AU - Saijo, Nagahiro
AU - Nishio, Kazuto
AU - Fujimoto, Junichiro
AU - Nomura, Masaharu
AU - Oda, Yoshiya
AU - Lindmark, Bertil
AU - Maniwa, Jiro
AU - Hibino, Hitoshi
AU - Unno, Michiaki
AU - Ito, Toshinori
AU - Sawa, Yoshiki
AU - Tojo, Hiromasa
AU - Egawa, Shin
AU - Edula, Goutham
AU - Lopez, Mary
AU - Wigmore, Murray
AU - Inase, Naohiko
AU - Yoshizawa, Yasuyuki
AU - Nomura, Fumio
AU - Marko-Varga, György
PY - 2011
Y1 - 2011
N2 - Lung cancer, COPD and cardiovascular diseases are highlighted as some of the most common disease that cause mortality, and for that reason are the most active areas for drug development. This perspective paper overviews the urgent need to develop a health care system for a rapidly growing patient population in Japan, including forthcoming demands on clinical care, expecting outcomes, and economics. There is an increasing requirement to build on the strengths of the current health care system, thereby delivering urgent solutions for the future. There is also a declaration from the Ministry of Health, Labour and Welfare (MHLW), to develop new biomarker diagnostics, which is intended for patient stratification, aiding in diagnostic phenotype selection for responders to drug treatment of Japanese patients. This perspective was written by the panel in order to introduce novel technologies and diagnostic capabilities with successful implementation. The next generation of personalized drugs for targeted and stratified patient treatment will soon be available in major disease areas such as, lifestyle-related cancers, especially lung cancers with the highest mortality including a predisposing disorder chronic obstructive pulmonary disease, cardiovascular disease, and other diseases. Mass spectrometric technologies can provide the "phenotypic fingerprint" required for the concept of Personalized Medicine. Mass spectrometry-driven target biomarker diagnoses in combination with high resolution computed tomography can provide a critical pathway initiative facilitated by a fully integrated e-Health infrastructure system. We strongly recommend integrating validated biomarkers based on clinical proteomics, medical imaging with clinical care supported by e-Health model to support personalized treatment paradigms to reduce mortality and healthcare costs of chronic and co-morbid diseases in the elderly population of Japan. (C) 2011 Published by Elsevier B.V.
AB - Lung cancer, COPD and cardiovascular diseases are highlighted as some of the most common disease that cause mortality, and for that reason are the most active areas for drug development. This perspective paper overviews the urgent need to develop a health care system for a rapidly growing patient population in Japan, including forthcoming demands on clinical care, expecting outcomes, and economics. There is an increasing requirement to build on the strengths of the current health care system, thereby delivering urgent solutions for the future. There is also a declaration from the Ministry of Health, Labour and Welfare (MHLW), to develop new biomarker diagnostics, which is intended for patient stratification, aiding in diagnostic phenotype selection for responders to drug treatment of Japanese patients. This perspective was written by the panel in order to introduce novel technologies and diagnostic capabilities with successful implementation. The next generation of personalized drugs for targeted and stratified patient treatment will soon be available in major disease areas such as, lifestyle-related cancers, especially lung cancers with the highest mortality including a predisposing disorder chronic obstructive pulmonary disease, cardiovascular disease, and other diseases. Mass spectrometric technologies can provide the "phenotypic fingerprint" required for the concept of Personalized Medicine. Mass spectrometry-driven target biomarker diagnoses in combination with high resolution computed tomography can provide a critical pathway initiative facilitated by a fully integrated e-Health infrastructure system. We strongly recommend integrating validated biomarkers based on clinical proteomics, medical imaging with clinical care supported by e-Health model to support personalized treatment paradigms to reduce mortality and healthcare costs of chronic and co-morbid diseases in the elderly population of Japan. (C) 2011 Published by Elsevier B.V.
KW - Lung cancer
KW - Chronic Obstructive Pulmonary
KW - Disease
KW - Proteomics
KW - Biomarker
KW - Mass spectrometry
KW - Diagnosis
U2 - 10.1016/j.jprot.2010.12.006
DO - 10.1016/j.jprot.2010.12.006
M3 - Review article
C2 - 21184850
SN - 1874-3919
VL - 74
SP - 759
EP - 764
JO - Journal of Proteomics
JF - Journal of Proteomics
IS - 6
ER -
